MedStar Authors catalog › Details for: Impact of transcatheter aortic valve replacement on risk profiles of surgical aortic valve replacement patients.
Normal view MARC view ISBD view

Impact of transcatheter aortic valve replacement on risk profiles of surgical aortic valve replacement patients.

by Craig, Paige; Rogers, Toby; Zou, Quan; Torguson, Rebecca; Okubagzi, Petros; Thourani, Vinod H; Corso, Paul J; Shults, Christian; Waksman, Ron.
Citation: Cardiovascular Revascularization Medicine. 2020 Apr 29.Journal: Cardiovascular revascularization medicine : including molecular interventions.Published: ; 2020ISSN: 1878-0938.Full author list: Craig P; Rogers T; Zou Q; Torguson R; Okubagzi PG; Ehsan A; Goncalves J; Hahn C; Bilfinger T; Buchanan S; Garrett R; Thourani VH; Corso P; Shults C; Waksman R.UI/PMID: 32387217.Subject(s): IN PROCESS -- NOT YET INDEXEDInstitution(s): MedStar Heart & Vascular InstituteActivity type: Journal Article.Medline article type(s): Journal ArticleOnline resources: Click here to access online Digital Object Identifier: (Click here) Abbreviated citation: Cardiovasc Revasc Med. 2020 Apr 29.Local Holdings: Available in print through MWHC library: 2002 - present.Abstract: BACKGROUND: The advent of transcatheter aortic valve replacement (TAVR) has changed which patients undergo surgical aortic valve replacement (SAVR). We sought to understand the impact of TAVR on the characteristics of SAVR patients in the United States.Abstract: METHODS: A cohort of 2959 patients who underwent isolated SAVR at 11 US hospitals that perform both TAVR and SAVR from 2013 through 2017 were grouped by the Society of Thoracic Surgeons (STS) Adult Cardiac Surgery Database version (v)2.73 (2011-2014), v2.81 (2014-2017), and v2.9 (2017) to assess temporal trends in patient characteristics.Abstract: RESULTS: Over time, SAVR patients were younger with fewer preoperative comorbidities. There was a significant decrease in median STS predicted risk of mortality (PROM) score (2.0 vs. 1.8 vs. 1.3, p < 0.001, in v2.73 vs. v2.81 vs. v2.9). Specifically, there were fewer high-risk (STS PROM > 8%: 4.3% vs. 4.7% vs. 1.2%, p = 0.03) and intermediate-risk (STS PROM 4% to 8%: 16.3% vs. 11.7% vs. 4.3%, p < 0.001) patients. The proportion of patients with bicuspid aortic valve disease increased significantly (11.2% vs. 26.9% vs. 36.6%, p < 0.001). There were no differences in operative mortality (1.9% vs. 2.1% vs. 1.4%, p = 0.75).Abstract: CONCLUSIONS: The introduction of TAVR has already impacted the demographics, clinical characteristics and risk profiles of patients undergoing SAVR in the US. Now that TAVR is approved for low-risk patients, SAVR is likely to be reserved for younger patients who are willing to receive a mechanical valve and for patients with aortopathy, coronary artery disease, or concomitant mitral or tricuspid pathology. Copyright (c) 2020 Elsevier Inc. All rights reserved.

Powered by Koha